Dr Deborah Dunsire appointed as CEO of EnVivo
EnVivo Pharmaceuticals announced today that Deborah Dunsire, M.D. has been appointed as the new president and chief executive officer. The announcement comes just two months after Dr. Dunsire announced her retirement from Millennium Pharmaceuticals, Inc., now Millennium: The Takeda Oncology Company.
Deborah will also join the board of directors at Envivo, a company which is dedicated to discovering and developing small molecule therapeutics for disorders of the central nervous system (CNS).
Deborah brings with her more than 25 years of scientific, clinical, operational and commercial experience, in addition to proven leadership in the biological and pharmaceutical industry.
Related news:
Dunsire makes quick leap from Millennium to fast-growing EnVivo (Fierce Biotech)
Reference links:
EnVivo Pharmaceuticals Announces Appointment of Deborah Dunsire, M.D., as President and Chief Executive Officer (Market Watch)